The second chapter of Indian Cancer Congress (ICC) 2017 will be
held from November 8-12, 2017 at the Clarks Convention Centre in
Bengaluru. Cancer being a non-communicable, conquerable lifestyle disease
and rapidly changing scenario of cancer worldwide is providing new insights
into the diagnosis, treatment and rehabilitation of cancer. The aim of the
conference, its four major national oncology partners and Karnataka government
is to provide a platform and spread cancer awareness through various
initiatives. Bengaluru, known as the silicon valley of India attracts a large
number of tourists every year and is one of the most advanced destinations for
healthcare in India.
The conference will see prominent national and International
delegates in multidisciplinary specialties such as surgical, medical,
radiation oncology, oncopath, genomics, radiology, scientists and research come
together in Bangalore. Karnataka government understands the implication of
cancer and hence, is one of the first to announce it as a “Notifiable Disease”.
Along with that, Karnataka government will take various initiatives for
oncology awareness and treatment at district and its plans to open
super-specialty hospitals.Other highlights of the conference include a major
step by National Centre for Disease Informatics (NCDI), the launch of
electronic mortality death certificates. Along with that, a full day programme
on generic drugs has been organized to explore the possibility of biosimilar
drugs.
A critical session on clinical trials will be held on 9TH NOV
in ICC for exploring ideas in cancer research. Indo-US and Indo-UK networking session on
collaboration of cancer research in India will be the key highlight of the
conference. Apart from these, original research papers will be presented during
the event and to encourage young oncologists in research various awards,
national and overseas fellowship has been sponsored.
During the press conference, Prof. K S Gopinath, Chairman,
and Prof. Ramesh.S.Bilimagga, ICC 2017, said, “We are very excited to
announce the second Indian Cancer Congress 2017 in Bengaluru this year with
tremendous support from the Government of Karnataka and Health Ministry. India
being the most progressive country in cancer research is a testimony to the hardwork
demonstrated by cancer specialist in the country and ICC 2017 is the biggest
oncology event showcasing it on the world map. The second congress will further
strengthen cancer research and development in the country.”
The four major oncology associations (Association of Radiation
Oncologists of India, Association of Surgical Oncologists, Indian Society of
Medical and Pediatric Oncology and the Indian Society of Oncology) of the
country come together to organize Indian Cancer congress (ICC) once every
four years. ICC 2017 also
enjoys support of over 4 professional bodies, 6 leading international associations involved in
cancer care. With a confirmed faculty of over 230 global thought leaders, ICC
has already received 3500+ delegate registration for the conference Kiran Mazumdar
Shaw chairman and MD of Biocon, the leading biopharmaceutical
company is the patron of this conference.
The conference will benefit the cancer care society and aid in
further research and development. There are around 3,300,000 cancer patients in
India and each year around 600,000 patients die and doctors diagnose 1,000,000
new cancer cases. India bears a disproportionate amount of cancer cases and
possesses 50% of the world’s oral cancer cases. On the other hand, Bengaluru
has seen a massive growth of cancer cases with approximately 113 cases for
every one lakh male and 139 cases for every one lakh female according to
population based cancer registry.
Four days of program as well as a day of pre-conference workshop
will be held. The program will consist of presentations, panel, round table
discussions, and lectures with an emphasis on audience participation. The ICC
will help care providers implement new ideas and research into their practice
as well as further the discussion of best practices to curtail the rapid growth
of cancer cases and provide quality care to patients.
No comments:
Post a Comment